These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 26657501

  • 1. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
    Li CC, Yang JC, Lu MC, Lee CL, Peng CY, Hsu WY, Dai YH, Chang FR, Zhang DY, Wu WJ, Wu YC.
    Oncotarget; 2016 Jan 12; 7(2):1947-59. PubMed ID: 26657501
    [Abstract] [Full Text] [Related]

  • 2. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q, Shen LY, Dong B, Fu H, Kang XZ, Yang YB, Dai L, Yan WP, Xiong HC, Liang Z, Chen KN.
    Cancer Lett; 2018 Sep 28; 432():56-68. PubMed ID: 29890208
    [Abstract] [Full Text] [Related]

  • 3. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
    Kim H, Cho U, Hong SH, Park HS, Kim IH, An HJ, Shim BY, Kang JH.
    Oncol Res; 2024 Sep 28; 32(6):1021-1030. PubMed ID: 38827321
    [Abstract] [Full Text] [Related]

  • 4. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Meng Y, Chen CW, Yung MMH, Sun W, Sun J, Li Z, Li J, Li Z, Zhou W, Liu SS, Cheung ANY, Ngan HYS, Braisted JC, Kai Y, Peng W, Tzatsos A, Li Y, Dai Z, Zheng W, Chan DW, Zhu W.
    Cancer Lett; 2018 Aug 01; 428():104-116. PubMed ID: 29704517
    [Abstract] [Full Text] [Related]

  • 5. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K, Geist K, Stuhldreier F, Schumacher L, Blümel L, Remke M, Wesselborg S, Stork B, Klöcker N, Bormann S, Roos WP, Honnen S, Fritz G.
    Cancer Lett; 2018 Aug 28; 430():34-46. PubMed ID: 29753759
    [Abstract] [Full Text] [Related]

  • 6. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
    Wu M, Chen J, Wang Y, Hu J, Liu C, Feng C, Zeng X.
    Oncotarget; 2015 Oct 13; 6(31):30887-901. PubMed ID: 26429874
    [Abstract] [Full Text] [Related]

  • 7. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F, George J, Schmitt A, Beleggia F, Rehkämper T, Hermann S, Walter V, Weber JP, Thomas RK, Wittersheim M, Büttner R, Persigehl T, Reinhardt HC.
    Sci Rep; 2017 Nov 14; 7(1):15511. PubMed ID: 29138515
    [Abstract] [Full Text] [Related]

  • 8. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Gomes LR, Rocha CRR, Martins DJ, Fiore APZP, Kinker GS, Bruni-Cardoso A, Menck CFM.
    Cell Death Dis; 2019 Jun 12; 10(6):459. PubMed ID: 31189884
    [Abstract] [Full Text] [Related]

  • 9. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
    Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, Jeong SH, Lee YJ, Ko GH, Kim J, Won Lee C, Soo Kang S, Yoo J.
    Int J Cancer; 2014 Oct 01; 135(7):1553-63. PubMed ID: 24585459
    [Abstract] [Full Text] [Related]

  • 10. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells.
    Chen S, Chen X, Xie G, He Y, Yan D, Zheng D, Li S, Fu X, Li Y, Pang X, Hu Z, Li H, Tan W, Li J.
    Oncotarget; 2016 Jun 28; 7(26):40362-40376. PubMed ID: 27246979
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of chloroquine in combination with Cisplatin in human gastric cancer xenografts.
    Zhang HQ, Fang N, Liu XM, Xiong SP, Liao YQ, Jin WJ, Song RF, Wan YY.
    Asian Pac J Cancer Prev; 2015 Jun 28; 16(9):3907-12. PubMed ID: 25987058
    [Abstract] [Full Text] [Related]

  • 12. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z, Liu S, Ding K, Ding S, Li C, Lu J, Gao D, Zhang T, Bi D.
    Tumour Biol; 2016 Nov 28; 37(11):15133-15143. PubMed ID: 27677286
    [Abstract] [Full Text] [Related]

  • 13. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
    Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, Lu B, Liu G, Wang Z.
    PLoS One; 2015 Nov 28; 10(5):e0114586. PubMed ID: 25992654
    [Abstract] [Full Text] [Related]

  • 14. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H, Shao F, Martin S, Xu X, Deng CX.
    Sci Rep; 2017 Mar 06; 7():43517. PubMed ID: 28262781
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ.
    Cancer Lett; 2016 Dec 01; 383(1):41-52. PubMed ID: 27693461
    [Abstract] [Full Text] [Related]

  • 16. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in KRAS-Mutant Cancer Cells.
    Erber J, Steiner JD, Isensee J, Lobbes LA, Toschka A, Beleggia F, Schmitt A, Kaiser RWJ, Siedek F, Persigehl T, Hucho T, Reinhardt HC.
    Cancer Res; 2019 Oct 01; 79(19):4855-4868. PubMed ID: 31405847
    [Abstract] [Full Text] [Related]

  • 17. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity.
    Ishiguro H, Kawahara T, Zheng Y, Kashiwagi E, Li Y, Miyamoto H.
    Cancer Chemother Pharmacol; 2014 Aug 01; 74(2):249-55. PubMed ID: 24880571
    [Abstract] [Full Text] [Related]

  • 18. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
    Guo Y, Wang J, Benedict B, Yang C, van Gemert F, Ma X, Gao D, Wang H, Zhang S, Lieftink C, Beijersbergen RL, Te Riele H, Qiao X, Gao Q, Sun C, Qin W, Bernards R, Wang C.
    Genome Med; 2021 Oct 18; 13(1):166. PubMed ID: 34663432
    [Abstract] [Full Text] [Related]

  • 19. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
    Job A, Schmitt LM, von Wenserski L, Lankat-Buttgereit B, Gress TM, Buchholz M, Gallmeier E.
    Neoplasia; 2018 Nov 18; 20(11):1135-1143. PubMed ID: 30257222
    [Abstract] [Full Text] [Related]

  • 20. PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
    Ro EJ, Ryu SH, Park EY, Ryu JW, Byun SJ, Heo SH, Kim KH, Baek IJ, Son BH, Lee SW.
    Breast Cancer Res Treat; 2020 Aug 18; 182(3):591-600. PubMed ID: 32529408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.